Figure 5. Radiosensitizing effects of vosaroxin on tumor weight and time to progression in xenograft models.

To assess the effect on tumors in an in vivo model, 1 × 10⁶ cells of U251, U87MG, and T98G GBM cells were subcutaneously injected in female cd1 nu/nu mice. When tumors reached a volume of 80 mm³ (about 10 days after cell injection), animals were randomized to receive radiotherapy (RT) alone (1 single dose of 4 Gy), vosaroxin (VSR; 10 mg/kg q 5 d for 5 wk), or vosaroxin (10 mg/kg q 5 d for 5 wk) plus RT (1 single dose of 4 Gy administered after 3 days of vosaroxin treatment). These treatments were compared with standard therapies consisting of temozolomide (TMZ; 16 mg/kg ′ 5 consecutive days) and temozolomide plus RT. Changes in tumor volumes were measured over time. After 35 days, animals were sacrificed and tumors harvested and weighed. Final tumor weights (at day 35) and Kaplan-Meier analysis of time to progression are shown for: (A, B) U87MG; (C, D) U251; and (E, F) T98G xenograft models. CTRL: control.